12 issues of the online newsletter Nordic Life Science Careers.

Elicera Therapeutics has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to move its CARMA study of the CAR T-cell therapy ELC-301 in B-cell lymphoma into Phase IIa.

A new study co-authored by Jonathan Ilicki, Life Science Strategy Lead at the Swedish venture capital firm Industrifonden, finds that investment and business-development professionals often misjudge rare-disease assets, underestimating launch performance and misreading when the assets are most commonly acquired.

Throughout her career, customer centricity and a passion for solving unmet medical needs have driven Norwegian Lena Nymo Helli. This year, she joined the Danish company Coloplast as Country Manager for Norway.

US President Donald Trump said on Friday September 18, 2026, that his administration plans to recommend that vaccine makers split certain childhood vaccines into five smaller doses given six months apart, which he expects to sharply reduce autism. He did not name the vaccines or cite evidence.